 |
Chemotherapy for non-seminoma with poor prognosis |
Advanced germ cell cancer |
K. Fizazi |
|
Chemotherapy for seminoma and non-seminoma with good and intermediate prognosis |
Advanced germ cell cancer |
S. Culine |
|
Extragonadal germ cell tumors |
Advanced germ cell cancer |
C. Nichols |
|
Post-chemo surgery |
Advanced germ cell cancer |
P. Albers |
|
Post-surgical management |
Advanced germ cell cancer |
K. Fizazi |
|
Comparative genetics: clinical implications |
Biology of germ cell tumors |
L. Looijenga |
|
Potential (new) molecular targets for treatment of germ cell cancer |
Biology of germ cell tumors |
F. Algaba |
|
Why germ cell tumors are so platinum sensitive and some resistant |
Biology of germ cell tumors |
D. Feldman |
|
Control investigations under treatment to guide further treatment |
Diagnostic measures for staging |
T. Gauler |
|
Predictive factors: What to do before start of treatment |
Diagnostic measures for staging |
P. Warde |
|
Prognosis-oriented planning of imaging for staging |
Diagnostic measures for staging |
G. Rustin |
|
The role of PET after chemotherapy |
Diagnostic measures for staging |
M. De Santis |
|
How to follow up patients |
Late problems and supportive management |
G. Rustin |
|
Optimal supportive management of the patient |
Late problems and supportive management |
K. Jordan |
|
Second/long-term cancer risks |
Late problems and supportive management |
S. van de Belt |
|
HIV and germ cell cancer |
n/a |
T. Powles |
|
Management of Brain Metastases |
n/a |
S. Fossa |
|
Management of differentiated teratoma-the growing teratoma syndrome |
n/a |
R. Salvioni |
|
Presentation of the Amsterdam Consensus |
Quality assurance issues |
P. Laguna |
|
The international experience |
Quality assurance issues |
J.P. Droz |
BACK TO TOP
PRINT THIS PAGE